High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO

被引:106
作者
Willeit, M
Ginovart, N
Kapur, S
Houle, S
Hussey, D
Seeman, P
Wilson, AA
机构
[1] Univ Toronto, Ctr Addict & Mental Hlth, Positron Emiss Tomog Ctr, Toronto, ON M5S 2S1, Canada
[2] Univ Toronto, Dept Pharmacol, Toronto, ON M5S 2S1, Canada
[3] Med Univ Vienna, Dept Gen Psychiat, Vienna, Austria
基金
加拿大健康研究院;
关键词
dopamine; high affinity; agonist; PET; G protein; globus pallidus;
D O I
10.1016/j.biopsych.2005.09.017
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The high-affinity states of dopamine D2-receptors (D2(high)) are postulated to be functionally responsible for signal transduction. At present, no useful in vivo method exists to selectively measure D2(high) in humans, as current D2 radioligands for positron emission tomography (PET) are either not D2-selective or do not differentiate between D2-high and low-affinity states. The D2 agonist (+)-PHNO[(+)4-propyl-9-hydroxynaphthoxazine] was labeled with carbon-11 and studied with PET. Eight [C-11]-(+)-PHNO scans were acquired in four healthy volunteers. We observed greatest [C-11]-(+)-PHNO in accumulation in caudate, putamen, and globus pallidus [binding potentials (BPs): 3.00 +/- .4, 3.10 +/- .2, and 4.17 +/- 1.2]. Small but detectable binding was indentified in the substantia nigra/ventrral tegmental area. Preliminary test-retest data in two subjects suggests BP-estimates to be reliable. Pre-treatment with haloperidol reduced BPs in regions showing specific binding with no detectable changes in cerebellum. Parallel imaging with [C-11]-raclopride showed substantial differences in the globus pallidus. [C-11]-(+)-PHNO proved to be a D2/3-receptor agonist-radioligand with good brain uptake and favorable kinetics for PET in humans. [C-11]-(+)-PHNO delineated D2/3-receptor rich brain regions with high signal-to-noise ratio. This is the first demonstration of a viable agonist-radioligand for D2 receptors in humans and opens the door for investigating D2(high) in health and disease.
引用
收藏
页码:389 / 394
页数:6
相关论文
共 43 条
[1]   Increased baseline occupancy of D2 receptors by dopamine in schizophrenia [J].
Abi-Dargham, A ;
Rodenhiser, J ;
Printz, D ;
Zea-Ponce, Y ;
Gil, R ;
Kegeles, LS ;
Weiss, R ;
Cooper, TB ;
Mann, JJ ;
Van Heertum, RL ;
Gorman, JM ;
Laruelle, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) :8104-8109
[2]   PARKINSONS-DISEASE MONOTHERAPY WITH CONTROLLED-RELEASE MK-458 (PHNO) - DOUBLE-BLIND-STUDY AND COMPARISON TO CARBIDOPA LEVODOPA [J].
AHLSKOG, JE ;
MUENTER, MD ;
BAILEY, PA ;
MILLER, PM .
CLINICAL NEUROPHARMACOLOGY, 1991, 14 (03) :214-227
[3]  
BROWN DJ, 1997, 12 INT S RAD CHEM UP, P565
[4]  
Bruecke T., 2000, Journal of Neurology, V247, P2
[5]   DOPAMINE-RECEPTORS IN HUMAN-BRAIN - AUTORADIOGRAPHIC DISTRIBUTION OF D2 SITES [J].
CAMPS, M ;
CORTES, R ;
GUEYE, B ;
PROBST, A ;
PALACIOS, JM .
NEUROSCIENCE, 1989, 28 (02) :275-290
[6]   AUTORADIOGRAPHIC LOCALIZATION AND QUANTIFICATION OF DOPAMINE D2 RECEPTORS IN NORMAL HUMAN-BRAIN WITH [H-3] N-NORMAL-PROPYLNORAPOMORPHINE [J].
CAMUS, A ;
JAVOYAGID, F ;
DUBOIS, A ;
SCATTON, B .
BRAIN RESEARCH, 1986, 375 (01) :135-149
[7]   SUSTAINED-RELEASE (+)-PHNO [MK-458 (HPMC)] IN THE TREATMENT OF PARKINSONS-DISEASE - EVIDENCE FOR TOLERANCE TO A SELECTIVE D2-RECEPTOR AGONIST ADMINISTERED AS A LONG-ACTING FORMULATION [J].
CEDARBAUM, JM ;
CLARK, M ;
TOY, LH ;
GREENPARSONS, A .
MOVEMENT DISORDERS, 1990, 5 (04) :298-303
[8]   NASOGASTRIC AND INTRAVENOUS INFUSIONS OF (+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO) IN PARKINSONS-DISEASE [J].
COLEMAN, RJ ;
QUINN, NP ;
TRAUB, M ;
MARSDEN, CD .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (02) :102-105
[9]   Kinetics of the uptake and distribution of the dopamine D2,3 agonist (R)-N-[1-11C]n-propylnorapomorphine in brain of healthy and MPTP-treated Gottingen miniature pigs [J].
Cumming, P ;
Gillings, NM ;
Jensen, SB ;
Bjarkam, C ;
Gjedde, A .
NUCLEAR MEDICINE AND BIOLOGY, 2003, 30 (05) :547-553
[10]  
DEKEYSER J, 1985, J NEUROCHEM, V45, P977